UAB 1033/TBCRC 018: A Phase II Study of the PARP Inhibitor, INIPARIB (BSI-201) in Combination with Chemotherapy to Treat Triple Negative Breast Cancer Brain Metastasis

Grant

Date/time Interval

  • February 4, 2011 - February 3, 2016
  • Total Award Amount

  • 30000.00
  • Direct Costs

  • 23810.00
  • Sponsor Award Id

  • LCCC0919
  • Contributor

  • Carpenter, John   Principal Investigator